Advances in the protective mechanism and clinical implications of autophagy in liver failure

Yangyang HU; Xing ZHANG; Yue LUO; Yadong WANG; Caiyan ZHAO

doi:10.3969/j.issn.1001-5256.2023.10.030

Volume 39 Issue 10

Oct. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(10): 2485-2490

PDF( 747 KB)

Advances in the protective mechanism and clinical implications of autophagy in liver failure

DOI: 10.3969/j.issn.1001-5256.2023.10.030

Department of Infectious Diseases，Xiangjiang Branch of The Third Hospital of Hebei Medical University，Shijiazhuang 050051，China

Research funding:

Natural Science Foundation of Hebei Province (H2020206036);

Key Research and Development Project of Hebei Province (21377756D)

More Information

Corresponding author: WANG Yadong， wangyadong8060@126.com （ORCID： 0000－0003－0140－0674）
Received Date: 2023-02-08
Published Date: 2023-10-30

Abstract

Abstract

‍Liver failure is a serious clinical syndrome of liver disease with critical condition and high mortality， and besides liver transplantation， there is still a lack of satisfactory radical treatment methods. The pathogenesis of liver failure is complex and remains unclear， involving a variety of factors that affect the balance of hepatocyte necrosis and regeneration. This article summarizes autophagy as the key pathway for maintaining cell homeostasis and points out that autophagy plays an important protective role in the pathogenesis of liver failure by regulating NLRP3 inflammasome activation， reducing oxidative stress， and inhibiting cell apoptosis. Meanwhile， it is believed that the molecular signaling pathways targeting autophagy， such as exosomes and peroxisome proliferator－activated receptor α， participate in antagonizing the development and progression of liver failure and will become important ideas and directions for molecular targeted therapies for liver failure.
- Liver Failure,
- Autophagy,
- Molecular Targeted Therapy

FullText(HTML)

References(40)

References

[1]	VARGAS J, HAMASAKI M, KAWABATA T, et al. The mechanisms and roles of selective autophagy in mammals[J]. Nat Rev Mol Cell Biol, 2023, 24( 3): 167－ 185. DOI: 10.1038/s41580－022－00542－2.
[2]	REN F, ZHANG L, ZHANG X, et al. Inhibition of glycogen synthase kinase 3β promotes autophagy to protect mice from acute liver failure mediated by peroxisome proliferator－activated receptor α[J]. Cell Death Dis, 2016, 7( 3): e2151. DOI: 10.1038/cddis.2016.56.
[3]	XUE R, YANG J, JIA L, et al. Mitofusin2, as a protective target in the liver, controls the balance of apoptosis and autophagy in acute－on－chronic liver failure[J]. Front Pharmacol, 2019, 10: 601. DOI: 10.3389/fphar.2019.00601.
[4]	WU Y, HE Y, WANG F, et al. Lipopolysaccharide inhibits autophagy and promotes inflammatory responses via p38 MAPK－induced proteasomal degradation of Atg13 in hepatic stellate cells[J]. Mediators Inflamm, 2022, 2022: 9603989. DOI: 10.1155/2022/9603989.
[5]	TANG L, WANG X, ZHAO R, et al. Yi－Qi－Jian－Pi formula ameliorates immune function in acute－on－chronic liver failure by upregulating autophagy and mitochondrial biogenesis in CD8(+) T lymphocytes[J]. J Ethnopharmacol, 2023, 308: 116276. DOI: 10.1016/j.jep.2023.116276.
[6]	STAVROPOULOS A, DIVOLIS G, MANIOUDAKI M, et al. Coordinated activation of TGF－β and BMP pathways promotes autophagy and limits liver injury after acetaminophen intoxication[J]. Sci Signal, 2022, 15( 740): eabn4395. DOI: 10.1126/scisignal.abn4395.
[7]	NI HM, BOCKUS A, BOGGESS N, et al. Activation of autophagy protects against acetaminophen－induced hepatotoxicity[J]. Hepatology, 2012, 55( 1): 222－ 232. DOI: 10.1002/hep.24690.
[8]	HE YM, SHEN XL, GUO YN, et al. Yinhuang oral liquid protects acetaminophen－induced acute liver injury by regulating the activation of autophagy and Nrf2 signaling[J]. Ecotoxicol Environ Saf, 2022, 244: 114073. DOI: 10.1016/j.ecoenv.2022.114073.
[9]	FAN Z, LI Y, CHEN S, et al. Magnesium isoglycyrrhizinate ameliorates concanavalin A－induced liver injury by inhibiting autophagy[J]. Front Pharmacol, 2022, 12: 794319. DOI: 10.3389/fphar.2021.794319.
[10]	JIA Y, MA L, WANG Y, et al. NLRP3 inflammasome and related cytokines reflect the immune status of patients with HBV－ACLF[J]. Mol Immunol, 2020, 120: 179－ 186. DOI: 10.1016/j.molimm.2020.01.011.
[11]	HAN M, LI S, LI L. Verapamil inhibits early acute liver failure through suppressing the NLRP3 inflammasome pathway[J]. J Cell Mol Med, 2021, 25( 13): 5963－ 5975. DOI: 10.1111/jcmm.16357.
[12]	WANG Y, CHEN Q, JIAO F, et al. Histone deacetylase 2 regulates ULK1 mediated pyroptosis during acute liver failure by the K68 acetylation site[J]. Cell Death Dis, 2021, 12( 1): 55. DOI: 10.1038/s41419－020－03317－9.
[13]	SHAN S, SHEN Z, ZHANG C, et al. Mitophagy protects against acetaminophen－induced acute liver injury in mice through inhibiting NLRP3 inflammasome activation[J]. Biochem Pharmacol, 2019, 169: 113643. DOI: 10.1016/j.bcp.2019.113643.
[14]	HAN J, BAE J, CHOI CY, et al. Autophagy induced by AXL receptor tyrosine kinase alleviates acute liver injury via inhibition of NLRP3 inflammasome activation in mice[J]. Autophagy, 2016, 12( 12): 2326－ 2343. DOI: 10.1080/15548627.2016.1235124.
[15]	BIASIZZO M, KOPITAR－JERALA N. Interplay between NLRP3 inflammasome and autophagy[J]. Front Immunol, 2020, 11: 591803. DOI: 10.3389/fimmu.2020.591803.
[16]	WANG T, LU Z, QU XH, et al. Chrysophanol－8－O－glucoside protects mice against acute liver injury by inhibiting autophagy in hepatic stellate cells and inflammatory response in liver－resident macrophages[J]. Front Pharmacol, 2022, 13: 951521. DOI: 10.3389/fphar.2022.951521.
[17]	VARıŞLı B, CAGLAYAN C, KANDEMIR FM, et al. Chrysin mitigates diclofenac－induced hepatotoxicity by modulating oxidative stress, apoptosis, autophagy and endoplasmic reticulum stress in rats[J]. Mol Biol Rep, 2023, 50( 1): 433－ 442. DOI: 10.1007/s11033－022－07928－7.
[18]	OAMI T, WATANABE E, HATANO M, et al. Blocking liver autophagy accelerates apoptosis and mitochondrial injury in hepatocytes and reduces time to mortality in a murine sepsis model[J]. Shock, 2018, 50( 4): 427－ 434. DOI: 10.1097/SHK.0000000000001040.
[19]	WANG H, NI HM, CHAO X, et al. Double deletion of PINK1 and Parkin impairs hepatic mitophagy and exacerbates acetaminophen－induced liver injury in mice[J]. Redox Biol, 2019, 22: 101148. DOI: 10.1016/j.redox.2019.101148.
[20]	SHEN Z, WANG Y, SU Z, et al. Activation of p62－keap1－Nrf2 antioxidant pathway in the early stage of acetaminophen－induced acute liver injury in mice[J]. Chem Biol Interact, 2018, 282: 22－ 28. DOI: 10.1016/j.cbi.2018.01.008.
[21]	RUART M, CHAVARRIA L, CAMPRECIÓS G, et al. Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury[J]. J Hepatol, 2019, 70( 3): 458－ 469. DOI: 10.1016/j.jhep.2018.10.015.
[22]	YANG J, LI J, GUO H, et al. An experimental study reveals the protective effect of autophagy against realgar－induced liver injury via suppressing ROS－mediated NLRP3 inflammasome pathway[J]. Int J Mol Sci, 2022, 23( 10): 5697. DOI: 10.3390/ijms23105697.
[23]	WANG Q, JIA F, GUO C, et al. PINK1/Parkin－mediated mitophagy as a protective mechanism against AFB(1)－induced liver injury in mice[J]. Food Chem Toxicol, 2022, 164: 113043. DOI: 10.1016/j.fct.2022.113043.
[24]	AHMEDY OA, SALEM HH, SAYED NH, et al. Naringenin affords protection against lipopolysaccharide/D－galactosamine－induced acute liver failure: Role of autophagy[J]. Arch Biochem Biophys, 2022, 717: 109121. DOI: 10.1016/j.abb.2022.109121.
[25]	CHEN Q, WANG Y, JIAO FZ, et al. Histone deacetylase 6 inhibitor ACY1215 offers a protective effect through the autophagy pathway in acute liver failure[J]. Life Sci, 2019, 238: 116976. DOI: 10.1016/j.lfs.2019.116976.
[26]	TIAN Z, CHEN Y, YAO N, et al. Role of mitophagy regulation by ROS in hepatic stellate cells during acute liver failure[J]. Am J Physiol Gastrointest Liver Physiol, 2018, 315( 3): G374－G384. DOI: 10.1152/ajpgi.00032.2018.
[27]	JIA Y, LI Y, WANG YJ. Research progress on exosome targeted delivery of nucleic acid molecules[J]. China Med Herald, 2023, 20( 3): 33－ 36, 49. DOI: 10.20047/j.issn1673－7210.2023.03.07. 贾岳, 李妍, 王英骥. 外泌体靶向递送核酸类分子研究进展[J]. 中国医药导报, 2023, 20( 3): 33－ 36, 49. DOI: 10.20047/j.issn1673－7210.2023.03.07.
[28]	ZHENG J, WANG LR. Functions of exosomes on alcoholic liver disease[J/CD]. Chin J Liver Dis: Electronic Edition, 2022, 14( 2): 27－ 31. DOI: 10.3969/j.issn.1674－7380.2022.02.004. 郑洁, 王丽蕊. 外泌体在酒精性肝病中的功能[J/CD]. 中国肝脏病杂志(电子版), 2022, 14( 2): 27－ 31. DOI: 10.3969/j.issn.1674－7380.2022.02.004.
[29]	COLLETTI M, CEGLIE D, DI GIANNATALE A, et al. Autophagy and exosomes relationship in cancer: friends or foes?[J]. Front Cell Dev Biol, 2021, 8: 614178. DOI: 10.3389/fcell.2020.614178.
[30]	SHEN Y, MALIK SA, AMIR M, et al. Decreased hepatocyte autophagy leads to synergistic IL－1β and TNF mouse liver injury and inflammation[J]. Hepatology, 2020, 72( 2): 595－ 608. DOI: 10.1002/hep.31209.
[31]	JIAO Y, ZHANG Y, SHI HL, et al. A bioinformatics analysis of differentially expressed proteins in plasma exosome of acute－on－chronic liver failure patients with different prognoses[J]. J Clin Hepatol, 2021, 37( 4): 834－ 840. DOI: 10.3969/j.issn.1001－5256.2021.04.022. 焦彦, 张莹, 时红林, 等. 慢加急性肝衰竭不同预后患者血浆外泌体差异蛋白的生物信息学分析[J]. 临床肝胆病杂志, 2021, 37( 4): 834－ 840. DOI: 10.3969/j.issn.1001－5256.2021.04.022.
[32]	GAO S, FAN YC, HAN LY, et al. Serum exosomal long noncoding RNA nuclear－enriched abundant transcript 1 predicts 90－day mortality in acute－on－chronic hepatitis B liver failure[J]. Expert Rev Clin Immunol, 2021, 17( 7): 789－ 797. DOI: 10.1080/1744666X.2021.1933442.
[33]	JIAO Y, LU W, XU P, et al. Hepatocyte－derived exosome may be as a biomarker of liver regeneration and prognostic valuation in patients with acute－on－chronic liver failure[J]. Hepatol Int, 2021, 15( 4): 957－ 969. DOI: 10.1007/s12072－021－10217－3.
[34]	YANG B, DUAN W, WEI L, et al. Bone marrow mesenchymal stem cell－derived hepatocyte－like cell exosomes reduce hepatic ischemia/reperfusion injury by enhancing autophagy[J]. Stem Cells Dev, 2020, 29( 6): 372－ 379. DOI: 10.1089/scd.2019.0194.
[35]	LIN D, CHEN H, XIONG J, et al. Mesenchymal stem cells exosomal let－7a－5p improve autophagic flux and alleviate liver injury in acute－on－chronic liver failure by promoting nuclear expression of TFEB[J]. Cell Death Dis, 2022, 13( 10): 865. DOI: 10.1038/s41419－022－05303－9.
[36]	LIU YM, MA JH, ZENG QL, et al. MiR－19a affects hepatocyte autophagy via regulating lncRNA NBR2 and AMPK/PPARα in D－GalN/Lipopolysaccharide－stimulated hepatocytes[J]. J Cell Biochem, 2018, 119( 1): 358－ 365. DOI: 10.1002/jcb.26188.
[37]	JIANG N, ZHANG J, PING J, et al. Salvianolic acid B inhibits autophagy and activation of hepatic stellate cells induced by TGF－β1 by downregulating the MAPK pathway[J]. Front Pharmacol, 2022, 13: 938856. DOI: 10.3389/fphar.2022.938856.
[38]	GUO E, LI R, YANG J, et al. FK866 attenuates acute hepatic failure through c－jun－N－terminal kinase(JNK)－dependent autophagy[J]. Sci Rep, 2017, 7( 1): 2206. DOI: 10.1038/s41598－017－02318－7.
[39]	YANG Y, YING G, WU F, et al. sTim－3 alleviates liver injury via regulation of the immunity microenvironment and autophagy[J]. Cell Death Discov, 2020, 6: 62. DOI: 10.1038/s41420－020－00299－7.
[40]	WANG Y, WANG JL, MA HC, et al. Mesenchymal stem cells increase heme oxygenase 1－activated autophagy in treatment of acute liver failure[J]. Biochem Biophys Res Commun, 2019, 508( 3): 682－ 689. DOI: 10.1016/j.bbrc.2018.11.146.

Relative Articles

[1]	Wenjing NI, Nan GENG, Xue BAI, Jie LI. An excerpt of EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease in 2024[J]. Journal of Clinical Hepatology, 2024, 40(8): 1567-1574. doi: 10.12449/JCH240810
[2]	Xiaoyong DUO, Shijie ZHANG, Hongwei ZHANG, Jing YANG, Wenqiang WANG, Linzhi YU, Baocai ZHANG, Yicheng ZHUO, Yunchao JIA, Yan PENG, Shuai HU. Association between gallstones and metabolic syndrome in southern Xinjiang, China[J]. Journal of Clinical Hepatology, 2022, 38(8): 1859-1864. doi: 10.3969/j.issn.1001-5256.2022.08.026
[3]	CHEN Huan, LI Ting, WANG ZiJie, WANG ZhongQiong, LUO Gang, DENG MingMing. Influence of metabolic syndrome and its components on the prognosis of patients with pancreatic cancer[J]. Journal of Clinical Hepatology, 2020, 36(12): 2788-2794. doi: 10.3969/j.issn.1001-5256.2020.12.029
[4]	Tian Tian, Hu WenWei, Li Xue, Li Ji, Zhang Dan, Li ZhangZheng. Metabolic characteristics of nonalcoholic fatty liver disease and related risk factors in non-obese population[J]. Journal of Clinical Hepatology, 2020, 36(6): 1310-1313. doi: 10.3969/j.issn.1001-5256.2020.06.024
[5]	Niu ChunYan, Liu Qin, Luo XiaoChun. Reexamination of the diagnosis of fatty liver disease under the background of disease spectrum progression[J]. Journal of Clinical Hepatology, 2020, 36(10): 2356-2359. doi: 10.3969/j.issn.1001-5256.2020.10.043
[6]	Chinese Society of EndocrinologyChinese Medical Association. Consensus for diagnosis and treatment of nonalcoholic fatty liver diseases and metabolic disorders (2nd Edition)[J]. Journal of Clinical Hepatology, 2018, 34(10): 2103-2108. doi: 10.3969/j.issn.1001-5256.2018.10.010
[7]	Wu QiQi, Ma Yan, Wang XiaoBo, Xu Qiang, Wang Yan, Bai Li. Influence of metabolic syndrome on significant hepatic fibrosis in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(12): 2572-2577. doi: 10.3969/j.issn.1001-5256.2018.12.013
[8]	Zhou BingBing, Wang XueMei, Zhang Qian, Xu ShiYi, Dan ZhongYan, Lai YaXin, Wang HaoYu. Association between metabolic syndrome and gallstones[J]. Journal of Clinical Hepatology, 2017, 33(5): 880-882. doi: 10.3969/j.issn.1001-5256.2017.05.017
[9]	Xu BeiBei, Wang BingYuan. Nonalcoholic fatty liver disease and serum uric acid[J]. Journal of Clinical Hepatology, 2016, 32(3): 437-441. doi: 10.3969/j.issn.1001-5256.2016.03.007
[10]	Li LiangPing. Nonalcoholic fatty liver disease and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(3): 432-436. doi: 10.3969/j.issn.1001-5256.2016.03.006
[11]	Fan JianGao, Yan ShiYan. Metabolic syndrome and fatty liver[J]. Journal of Clinical Hepatology, 2016, 32(3): 407-410. doi: 10.3969/j.issn.1001-5256.2016.03.001
[12]	Zhao HongXin, Yan Rong, Niu ChunYan, Zhou YongLi, Wang Jia, Cao RuiQi. Prevalence and associated risk factors for obesity and nonalcoholic fatty liver disease in adolescents in Xi′an, Shaanxi province, China[J]. Journal of Clinical Hepatology, 2015, 31(8): 1248-1251. doi: 10.3969/j.issn.1001-5256.2015.08.016
[13]	Huang Ying, Chen Hong. Research progress in association between nonalcoholic fatty liver disease and gallstone disease[J]. Journal of Clinical Hepatology, 2014, 30(11): 1217-1220. doi: 10.3969/j.issn.1001-5256.2014.11.033
[14]	Fan JianGao, Zhu ChanYan. Strengthening research on relationship between metabolic syndrome and chronic liver disease[J]. Journal of Clinical Hepatology, 2013, 29(12): 881-884. doi: 10.3969/j.issn.1001-5256.2013.12.001
[15]	Yan Jie, Xie Wen. Relationship between metabolic syndrome and chronic hepatitis C[J]. Journal of Clinical Hepatology, 2013, 29(12): 887-889. doi: 10.3969/j.issn.1001-5256.2013.12.003
[16]	Li LiangPing, Zhong Huang. The study of cytokeratin 18 fragments and inflammation related factors in non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2012, 28(5): 359-363.
[17]	Zhang YiNing, Du HongWei, Liu YanJun, Wang ChaoXia. The diagnosis and risk factors for evaluation of nonalcoholic fatty liver disease in children and adolescents[J]. Journal of Clinical Hepatology, 2011, 27(7): 690-693.
[18]	Wu Tao, Yin ShouYi, Wang HongZhang, Zhang Hong, Jia Wei, Ji Guang. The clinical features and risk factors of patient with metabolic syndrome combined with non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2011, 27(10): 1036-1040.
[19]	Ruan JianWen, Yang Jing, Gao LiJuan. Advances in the relationship between metabolic syndrome and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2011, 27(10): 1102-1105.
[20]	Niu ChunYan, Yan Rong, Tian Yu, Ma HuiXia, Jiao ShuJiang. The prevalence of fatty liver disease and its relationship with metabolic syndrome[J]. Journal of Clinical Hepatology, 2010, 26(2): 167-169.

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	梁海锋，梁国志，袁观斗，郭振亚，何松青. 小肝综合征的发病机制及防治研究进展. 中华实验外科杂志. 2024(03): 639-643 .
2.	蔡景治，郑扬，仲伟明，刘波. 基于Bcl-2/CytC探究槲皮素对肝硬化大鼠微循环及肝脏病变的影响. 现代生物医学进展. 2023(05): 818-823 .
3.	赵媛，赵明，范玉梅，邵建营. 失代偿期乙型肝炎肝硬化患者不同病毒学应答状态对生存率及肝癌患病率的影响. 中国实用医刊. 2020(23): 50-52 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (498) PDF downloads(61)

Advances in the protective mechanism and clinical implications of autophagy in liver failure

DOI: 10.3969/j.issn.1001-5256.2023.10.030